Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.49 |
| ▸ | PCSK7 | Q16549 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030133 | 0.81 | KCNH2 (0.48) | CYP2C9MEN1KMT2AALDH1A1CYP2C19 | |
| SCHEMBL10638322 | 0.79 | NQO1 (0.73) | NQO1CYP2C9MEN1KMT2AALDH1A1 | |
| SCHEMBL11344241 | 0.77 | CYP2C9 (0.50) | CYP2C9MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL11373064 | 0.77 | MAPT (0.43) | NQO1CYP2C9MEN1KMT2AALDH1A1 | |
| SCHEMBL3130469 | 0.77 | EYA3 (0.72) | CYP2C9MEN1KMT2AALDH1A1CYP2C19 | |
| SCHEMBL11727102 | 0.76 | NQO1 (0.61) | NQO1CYP2C9MEN1KMT2AALDH1A1 | |
| SCHEMBL3119701 | 0.76 | EYA3 (0.77) | CYP2C9MEN1KMT2AALDH1A1CYP2C19 | |
| SCHEMBL11750759 | 0.76 | EYA3 (0.55) | NQO1CYP2C9MEN1KMT2AALDH1A1 | |
| SCHEMBL8788305 | 0.75 | EYA3 (0.51) | CYP2C9MEN1KMT2AALDH1A1CYP2C19 | |
| SCHEMBL8592840 | 0.73 | NPY1R (0.55) | ALDH1A1LMNATP53MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608633-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-7348345-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | DUNN JAMES P | 2007-08-02 | — | — | US | disclosed |
| US-7208509-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1608633-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1608629-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-10-07 | — | — | US | disclosed |
| WO-2004085411-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085406-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192704-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192704-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLA1, REV1 | NQO1 1262/4885CYP2C9 622/4885MEN1 4511/4885 |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLR2A, POLR2E | NQO1 1712/4885CYP2C9 808/4885MEN1 4616/4885 |
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | RRM2, RRM2B, SAMHD1 | NQO1 162/4885CYP2C9 1755/4885MEN1 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.